Maynard Um
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Misses Q1 EPS by 146c
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Misses Q3 EPS by 138c
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Files for 11.39M Share Offering by Selling Stockholders
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Cartesian Therapeutics (RNAC)
-
-
-
-
-
-
-
TD Cowen Starts Cartesian Therapeutics (RNAC) at Buy
-
-
-
-
-
-
-
Cartesian Therapeutics (RNAC) Reports Positive Topline Results from Phase 2b Trial of Descartes-08
466,309 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


